Stocks:
5,168
ETFs:
2,288
Exchanges:
11
Market Cap:
$63.92T
24h Vol:
$4.36B
Dominance:
MSFT:4.92%
Stocklytics Platform
Instrument logo  BSX
Boston Scientific Corp
BSX
72 / 100
S&P500
$68.49arrow_drop_down0.50%-$0.35

Income Statement (BSX)

itemDec 2023Sep 2023Jun 2023Mar 2023Dec 2022
EBIT$703.00M$593.00M$588.00M$552.00M$586.00M
EBITDA$1.01B$801.00M$798.00M$744.00M$785.00M
gross Profit$2.57B$2.41B$2.52B$2.34B$2.21B
NET Income$505.00M$504.00M$270.00M$314.00M$140.00M
total Revenue$3.72B$3.52B$3.59B$3.38B$3.24B

Balance Sheet (BSX)

itemDec 2023Sep 2023Jun 2023Mar 2023Dec 2022
cash Equivalents-$952.00M$426.00M$570.00M$928.00M
net Debt$8.62B$8.34B$9.02B$8.79B$8.35B
stockholders Equity$19.28B$18.88B$18.22B$17.85B$17.57B
total Assets$35.13B$34.04B$33.60B$32.89B$32.47B
total Debt$9.49B$9.29B$9.45B$9.36B$9.28B
total Liabilities$15.60B$14.91B$15.11B$14.78B$14.89B

Cash Flow (BSX)

itemDec 2023Sep 2023Jun 2023Mar 2023Dec 2022
financing Cash Flow$15.00M$16.00M$43.00M-$69.00M$1.00M
free Cash Flow$690.00M$492.00M$452.00M$69.00M$607.00M
investing Cash Flow--$1.52B-$840.00M-$484.00M-$2.01B
operating Cash Flow$957.00M$698.00M$658.00M$190.00M$807.00M

Boston Scientific Corp (BSX) Financials

The income statement of Boston Scientific Corp (BSX) provides a detailed overview of the company's financial performance. It includes information about the revenue generated, expenses incurred, and the resulting net income. For the latest financial year, the total revenue of Boston Scientific Corp was $10.74 billion. The gross profit for the same period was $8.15 billion. After deducting operating expenses, the company reported an operating income, also known as EBIT, of $1.83 billion. The EBITDA (earnings before interest, taxes, depreciation, and amortization) of Boston Scientific Corp is commonly used to assess its operating performance and profitability. It indicates the company's ability to generate earnings from its core operations. In the latest financial year, the EBITDA of Boston Scientific Corp was $2.88 billion. Net income from stockholders refers to the profit earned by the company after deducting taxes and interest expenses. For Boston Scientific Corp, the net income from stockholders for the most recent year was $1.14 billion. This represents the amount of profit available to the stockholders after all financial obligations have been met. The balance sheet of Boston Scientific Corp provides a snapshot of its financial position at a specific point in time. It includes information about the company's assets, liabilities, and stockholders' equity. As of the latest financial year, the total assets of Boston Scientific Corp were valued at $32.41 billion. The total liabilities, including both short-term and long-term debt, amounted to $17.86 billion. Stockholders' equity, which represents the value of the company's assets that belong to the shareholders, was $14.55 billion. Cash equivalents refer to highly liquid assets that can be easily converted into cash. For Boston Scientific Corp, the cash equivalents on its balance sheet amounted to $1.56 billion. This includes short-term investments and other highly liquid assets that can be readily accessed. Net debt is a measure of a company's financial leverage. It represents the difference between a company's total debt and its cash and cash equivalents. For Boston Scientific Corp, the net debt as of the latest financial year was $5.78 billion. This indicates the company's overall financial position after accounting for its obligations and available cash. Total debt refers to the aggregated amount of a company's outstanding debt obligations, including both short-term and long-term debt. Boston Scientific Corp reported a total debt of $11.33 billion for the most recent year. This includes the company's borrowings and other financial liabilities. Total liabilities represent the total amount of a company's obligations to external parties. It includes both short-term and long-term liabilities. For Boston Scientific Corp, the total liabilities amounted to $17.86 billion. This includes debts, payables, and other financial obligations. The cash flow statement of Boston Scientific Corp provides insights into the company's cash inflows and outflows. It includes information about operating cash flow, investing cash flow, and financing cash flow. Operating cash flow refers to the cash generated from a company's core operations. For Boston Scientific Corp, the operating cash flow for the latest financial year was $2.68 billion. This represents the cash generated from the company's day-to-day business activities. Financing cash flow represents the cash transactions related to the company's financing activities. This includes the issuance and repayment of debt, as well as the payment of dividends to shareholders. Boston Scientific Corp reported a financing cash flow of -$1.76 billion for the most recent year. This indicates a net outflow of cash from financing activities. Free cash flow is a measure of a company's ability to generate cash after deducting capital expenditures. For Boston Scientific Corp, the free cash flow for the latest financial year was $1.98 billion. This represents the cash available after the company has invested in its business. Investing cash flow represents the cash transactions related to the company's investment activities. This includes the purchase and sale of long-term assets, such as property, plant, and equipment. The investing cash flow of Boston Scientific Corp was -$1.92 billion for the most recent year, indicating a net outflow of cash from investment activities.

add Boston Scientific Corp to watchlist

Keep an eye on Boston Scientific Corp

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.